Edesa Biotech (EDSA) Operating Expenses (2013 - 2026)
Edesa Biotech (EDSA) posted Operating Expenses of $2.3 million for Q4 2025, down 5.22% sequentially from $2.5 million in Q3 2025, and up 23.32% YoY from $1.9 million in Q4 2024.
Edesa Biotech (EDSA) Operating Expenses (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Operating Expenses for 13 years, with the latest figure at $2.3 million in Q4 2025.
- Quarterly Operating Expenses rose 23.32% year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.4 million (up 18.4% YoY) and the FY2025 annual result came in at $7.9 million, up 12.78% from the prior year.
- Operating Expenses retreated to $2.3 million in Q4 2025 per EDSA's latest filing, from $2.5 million in the prior quarter.
- Over five years, Operating Expenses peaked at $9.5 million in Q1 2021 and troughed at $1.0 million in Q3 2024.
- A 5-year average of $3.3 million and a median of $2.4 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2021 and 2023: Operating Expenses jumped 484.62% in 2021, then plunged 64.39% in 2023.
- Over 5 years, Operating Expenses stood at $5.2 million in 2021, then tumbled by 53.92% to $2.4 million in 2022, then slipped by 21.9% to $1.9 million in 2023, then gained by 2.22% to $1.9 million in 2024, then advanced by 23.32% to $2.3 million in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $2.3 million, $2.5 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 541.02 Mn |
| 10 | Edesa Biotech | 41.48 Mn | 41.48 Mn | - | 5.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.52 Mn |
| Dec 31, 2025 | 2.34 Mn |
| Sep 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 1.90 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 2.22 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Sep 30, 2023 | 2.37 Mn |
| Jun 30, 2023 | 2.06 Mn |
| Mar 31, 2023 | 2.41 Mn |
| Dec 31, 2022 | 2.38 Mn |
| Sep 30, 2022 | 2.84 Mn |
| Jun 30, 2022 | 5.80 Mn |
| Mar 31, 2022 | 4.58 Mn |
| Dec 31, 2021 | 5.16 Mn |
| Sep 30, 2021 | 5.48 Mn |
| Jun 30, 2021 | 6.07 Mn |